Join

Compare · BBC vs RICE

BBC vs RICE

Side-by-side comparison of Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Rice Acquisition Corp. (RICE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BBC and RICE operate in n/a (n/a), so they compete in similar markets.
  • RICE carries a market cap of $536.2M.
  • RICE has more recent analyst coverage (1 ratings vs 0 for BBC).
MetricBBCRICE
Company
Virtus LifeSci Biotech Clinical Trials ETF
Rice Acquisition Corp.
Price
$46.01-0.22%
$18.23+0.52%
Market cap
-
$536.2M
1M return
+16.30%
-
1Y return
+151.01%
-
Sector
n/a
n/a
Industry
n/a
n/a
Exchange
NASDAQ
NYSE
IPO
n/a
2020
News (4w)
0
0
Recent ratings
0
1
BBC

Virtus LifeSci Biotech Clinical Trials ETF

The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.

RICE

Rice Acquisition Corp.

Rice Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Carnegie, Pennsylvania.

Latest BBC

Latest RICE